Akshay Vaishnaw Biography and Net Worth

Dr. Akshay Vaishnaw joined Alnylam Pharmaceuticals in 2006 as VP Clinical Research and has then subsequently served in various R&D roles with increasing responsibility. Akshay is currently the President of R&D. Prior to 2006, he was at Biogen as Senior Director, Translational Medicine.

Akshay received his M.D. from the University of Wales College of Medicine, U.K., and Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Fellow of the Royal College of Physicians, U.K. Akshay is a member of the Board of Directors for Editas Medicine Inc. and Scholar Rock Inc. From 2014-2018, he served as a Board member of Visterra, Inc.

What is Akshay Vaishnaw's net worth?: The estimated net worth of Akshay Vaishnaw is at least $4.82 million as of April 27th, 2023. Dr. Vaishnaw owns 17,890 shares of Alnylam Pharmaceuticals stock worth more than $4,816,167 as of March 27th. This net worth estimate does not reflect any other assets that Dr. Vaishnaw may own. Additionally, Dr. Vaishnaw receives an annual salary of $1,120,000.00 as Insider at Alnylam Pharmaceuticals. Learn More about Akshay Vaishnaw's net worth.
How old is Akshay Vaishnaw?: Dr. Vaishnaw is currently 61 years old. There are 5 older executives and no younger executives at Alnylam Pharmaceuticals. Learn More on Akshay Vaishnaw's age.
What is Akshay Vaishnaw's salary?: As the Insider of Alnylam Pharmaceuticals, Inc., Dr. Vaishnaw earns $1,120,000.00 per year. The highest earning executive at Alnylam Pharmaceuticals is Dr. Yvonne L. Greenstreet M.B.A., MBChB, CEO & Director, who commands a salary of $2,150,000.00 per year. Learn More on Akshay Vaishnaw's salary.
How do I contact Akshay Vaishnaw?: The corporate mailing address for Dr. Vaishnaw and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at investors@alnylam.com. Learn More on Akshay Vaishnaw's contact information.
Has Akshay Vaishnaw been buying or selling shares of Alnylam Pharmaceuticals?: Akshay Vaishnaw has not been actively trading shares of Alnylam Pharmaceuticals in the last ninety days. Most recently, Akshay Vaishnaw sold 2,392 shares of the business's stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $194.59, for a transaction totalling $465,459.28. Following the completion of the sale, the president now directly owns 17,890 shares of the company's stock, valued at $3,481,215.10. Learn More on Akshay Vaishnaw's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 206,204 shares worth more than $51,381,995.84. The most recent insider tranaction occured on February, 18th when EVP Kevin Joseph Fitzgerald sold 1,440 shares worth more than $362,246.40. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 2/18/2025.

Akshay Vaishnaw Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/27/2023	Sell	2,392	$194.59	$465,459.28	17,890
12/23/2021	Sell	2,879	$190.93	$549,687.47
6/18/2021	Sell	14,708	$175.00	$2,573,900.00	24,953
4/21/2021	Sell	2,732	$136.95	$374,147.40	22,908
4/19/2021	Sell	3,706	$137.67	$510,205.02	22,908
9/29/2020	Sell	971	$140.00	$135,940.00	15,090
4/20/2020	Sell	21,971	$140.00	$3,075,940.00	35,119
2/7/2020	Sell	23,708	$125.00	$2,963,500.00	30,923
3/14/2018	Sell	88,554	$143.10	$12,672,077.40	55,856
10/30/2017	Sell	33,666	$121.46	$4,089,072.36	45,201
5/23/2017	Sell	11,000	$75.00	$825,000.00	21,297
5/15/2017	Sell	43,750	$65.00	$2,843,750.00	43,047
11/30/2016	Sell	29,165	$44.99	$1,312,133.35	34,915
6/16/2015	Sell	8,750	$128.83	$1,127,262.50
3/17/2015	Sell	8,750	$116.86	$1,022,525.00
12/16/2014	Sell	10,626	$93.60	$994,593.60
9/16/2014	Sell	10,625	$72.04	$765,425.00
6/17/2014	Sell	10,625	$69.82	$741,837.50
3/18/2014	Sell	32,769	$73.95	$2,423,267.55
1/24/2014	Sell	7,890	$85.75	$676,567.50
12/17/2013	Sell	33,480	$60.72	$2,032,905.60	12,588
9/10/2013	Sell	6,250	$57.48	$359,250.00
6/11/2013	Sell	15,000	$31.08	$466,200.00

See Full Table

Akshay Vaishnaw Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $269.21

$268.53

$281.20

50 Day Range

MA: $258.98

$233.07

$290.70

2 Week Range

Now: $269.21

$141.98

$304.39

Volume

1,073,887 shs

Average Volume

805,772 shs

Market Capitalization

$34.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Akshay Vaishnaw Biography and Net Worth

What is Akshay Vaishnaw's net worth?

How old is Akshay Vaishnaw?

What is Akshay Vaishnaw's salary?

How do I contact Akshay Vaishnaw?

Has Akshay Vaishnaw been buying or selling shares of Alnylam Pharmaceuticals?

Who are Alnylam Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Alnylam Pharmaceuticals?